National Minority Quality Forum to introduce Clinical Trial Network
National Minority Quality Forum to introduce Clinical Trial Network

Bioanalytical

National Minority Quality Forum to introduce Clinical Trial Network

18 Feb, 2013

Published over 13 years ago. See the latest and most current information on Bioanalytical.

The National Minority Quality Forum has announced its collaboration with the National Health Index and Microsoft Corporation to introduce the National Clinical Trial Network (NCTN).

It is designed to address important challenges in clinical trials in the pharma industry, such as accelerating recruitment and diversity. The relationship will also enable NCTN to provide a platform for a detailed database of options.

It will also act as a data warehouse, providing patient registries, bio banks and community-level health statistics, meaning isolated data repositories can be turned into one integrated archive.

Michael Robinson , vice president of US Health and Life Sciences, said: "This collaboration with the National Health Index is truly a 21st century healthcare venture, using big data and Microsoft's proprietary software to give the research community a vast array of information and communications tools.

"We fully expect NCTN to transform clinical research in the United States. Biopharmaceutical companies continue to explore new ways to further enhance awareness and participation in clinical trials by a diverse patient population."

Mr Robinson went on to say that he wants partnership efforts such as the NCTN to promote awareness and create connectivity that can be transformed into increased diversity among clinical trial participants.

The National Health Index provides wide access to an array of healthcare information, relating to diseases such as diabetes, heart disease, cancer, AIDs and Hepatitis C.

Members from the National Minority Quality Forum and the American Association of Clinical Endocrinologists recently met at the Cardiometabolic Health Congress in Boston.

The event will be used to explore ways to boost cariometabolic risk factor control in diverse populations, while providing people with more care for disorders, representing number of risk factors such as high blood pressure, blood sugar, dyslipidemia and abdominal obesity.

Posted by Neil Clark

Latest News

Explore Our Other Sites

Labmate Online
Sharpen your chromatography skills with PhenoAcademy
Explore more Arrow
Envirotech Online
EU ETS benchmark update puts industrial emissions data under sharper scrutiny
Explore more Arrow
Pollution Solutions Online
DNV introduces new framework for measuring onboard carbon capture performance
Explore more Arrow
Petro Online
New test method ASTM D8606 has been officially released
Explore more Arrow